


**Supplemental Figure 1. Validation of the Nav1.8-Cre system.** (A) Confocal micrographs of spinal cord, DRG and skin taken from Nav1.8-Cre;Ai9 mice showing Nav1.8-positive neurons in the DRG and Nav1.8-afferents in spinal cord and skin labeled with td-Tomato (**red**). Sections were co-labeled with a nuclear marker DAPI (**blue**). Magnification 10x (**top**), 20x (**middle**), 60x (**bottom**) (scale bar=50 $\mu$ m). (B) Weights of Nav1.8-Cre;Ai9 mice in grams (gr) fed either RD (**blue**) or HFD (**red**) over a 10 week period (\*, p<0.05, \*\*, p<0.01, \*\*\*\*, p<0.0001.) (n= 8/group). (C) Blood glucose levels for both RD and HFD at various lengths of time on each diet, blood glucose levels were taken 120 minutes after injection of glucose (45% D-glucose solution (2mg glucose/1g animal body weight)) (\*\*\*, p<0.001, \*\*\*\*, P<0.0001) (n=8/group). p-values were calculated using two-way ANOVA , Bonferroni multiple comparison test. (D) Confocal micrographs of skin taken from Nav1.8-Cre;Ai9 mice that had been on either RD or HFD for 2 or 8 weeks showing td-Tomato (**red**), PGP 9.5 (**green**), and DAPI a nuclear marker (**blue**). At 8 weeks HFD mice showed a reduced number of nerve fibers crossing the epidermal-dermal junction (outlined in white). Magnification 60x (scale bar=50 $\mu$ m). Values are expressed as mean  $\pm$  S.E.M.


A

Pirt-GCaMP3 mice 6-12 weeks







B

Pirt-GCaMP3 mice 2-4 weeks




**Supplemental Figure 2. Onset of increased  $[Ca^{2+}]_i$  responses in diabetic DRG explants after 6 weeks on HFD.** (A, B)  $[Ca^{2+}]_i$  responses of acutely excised DRGs from Pirt-GCaMP3 mice to 2 $\mu$ M or 10 $\mu$ M capsaicin and 10mM, or 25mM high potassium buffer (HK). Data is shown as capsaicin or HK responsive DRG neurons as a percentage of total neurons that responded to 50mM HK. (A) Explants from HFD mice that had been on diet for 6-12 weeks showed increased responses to 2 $\mu$ M capsaicin compared to RD mice. There were also increased responses of HFD explants to 10mM HK compared to RD (\*\*,  $p < 0.01$ , \*\*\*\*,  $p < 0.0001$ ). At higher concentrations of capsaicin and HK there was no significant difference between RD and HFD mice (RD n=594 neurons n=18 explants; HFD n=844 neurons n=30 explants). (B) When these same experiments were done on explants from mice that had only been on RD or HFD for 2-4 weeks there was no significant difference in  $[Ca^{2+}]_i$  responses to capsaicin or HK (RD n=347 neurons n=16 explants; HFD n=504 neurons n=20 explants). This showed that the increased  $[Ca^{2+}]_i$  responses of Pirt-GCaMP3 explants are evident after 6 weeks on HFD. Values are expressed as mean  $\pm$  S.E.M. p-values were calculated by Mann-Whitney test.




**Supplemental Figure 3. Selective deletion of CXCR4 receptors from Nav1.8-positive DRG neurons did not alter the DRG neuronal phenotype or metabolic profile of mice fed HFD.** (A) Confocal micrographs from DRGs from mice with either heterozygous deletion of CXCR4 (Nav1.8-Cre;Ai9;CXCR4<sup>flox/+</sup>) or homozygous deletion (Nav1.8-Cre;Ai9;CXCR4<sup>flox/flox</sup>), showing td-Tomato (**red**) labeling Nav1.8-positive DRG neurons some of which are also labeled with a marker for non-peptidergic DRG neurons, IB4 (**blue**). Magnification 60x (scale bar=50µm). (B) The numbers of td-Tomato positive and IB4 positive neurons were quantified and there were no significant differences between mice with heterozygous (td-Tomato 85.5±0.5, IB4 36.4±2.5) and homozygous (td-Tomato 87.3±2.8, IB4 35.8±2.9) selective CXCR4 deletions (n=177, 154 neurons respectively). p-values were calculated by Mann-Whitney test. (C) Weights of mice in grams (gr) with either heterozygous deletion of CXCR4 (Nav1.8-Cre;Ai9;CXCR4<sup>flox/+</sup>) or homozygous deletion (Nav1.8-Cre;Ai9;CXCR4<sup>flox/flox</sup>) of CXCR4 from Nav1.8-positive neurons( \*, p<0.05, \*\*, p<0.01) (n=6/group). (D) Blood glucose levels of the same mice 120 minutes after injection of glucose (45% D-glucose solution (2mg glucose/1gr animal body weight)) (\*, p<0.05) (n=6/group). Values are expressed as mean ± S.E.M. p-values were calculated using one-way ANOVA, Bonferroni multiple comparison test.

A




B




**Supplemental Figure 4. Selective chemokine receptor CXCR4 deletion from Nav1.8-positive DRG neurons prevented the development of small-fiber degeneration in HFD-induced PDN.** (A) Confocal analysis of skin from mice with either heterozygous ( $Nav1.8-Cre;Ai9;CXCR4^{flox/+}$ ) or homozygous deletion ( $Nav1.8-Cre;Ai9;CXCR4^{flox/flox}$ ) of CXCR4 on either RD or HFD showing td-Tomato (**red**), immunolabeling with antibody against the protein gene product 9.5 (PGP 9.5) (**green**), and merged images with the nuclear marker DAPI (**blue**).  $Nav1.8-Cre;Ai9;CXCR4^{flox/+}$  RD mice had normal skin innervation whereas the same mice on HFD had reduced innervation. However, selective homozygous deletion of CXCR4 for mice on HFD prevented small-fiber degeneration. Magnification 60x (scale bar=50 $\mu$ m). (B) This effect was quantified using intra-epidermal nerve density (IENF density) which is expressed as the number of nerves crossing the epidermal-dermal junction (outlined in white) as a function of epidermal-dermal junction length. IENF densities calculated using both td-Tomato labeled fibers (red or pink) and PGP 9.5 fibers (shades of green) (\*,  $p < 0.05$ , \*\*,  $p < 0.01$ , \*\*\*,  $p < 0.001$ ) ( $n=7$  for all groups with 3 non-contiguous sections analyzed per sample). Values are expressed as mean  $\pm$  S.E.M. p-values were calculated using a two-way ANOVA with Dunnett's Multiple Comparison test.



A Pirt-GCaMP3 mice 6-12 weeks CXCL12



B Pirt-GCaMP3 mice 2-4 weeks CXCL12



**Supplemental Figure 5. Onset of increased  $[Ca^{2+}]_i$  responses following CXCL12 application after 6 weeks on HFD. (A, B)  $[Ca^{2+}]_i$  responses of acutely excised DRGs from Pirt-GCaMP3 mice to CXCL12. Data is shown as CXCL12 responsive DRG neurons as a percentage of total neurons that responded to a high potassium buffer (HK). (A) There were significantly more  $[Ca^{2+}]_i$  responses to CXCL12 (100 nM) in explants from HFD mice compared to RD fed non-diabetic controls after 6-12 weeks on diet (\*\*\*\*,  $p < 0.0001$ ) (HFD n=844 neurons n=30 explants; RD n=594 neurons n=18 explants). (B) In contrast,  $[Ca^{2+}]_i$  responses to CXCL12 were not different after 2-4 weeks on HFD or on RD (HFD n=504 neurons n=20 explants; RD n=347 neurons n=16 explants). Values are expressed as mean  $\pm$  S.E.M. p-values were calculated using Mann-Whitney test.**




**Supplemental Figure 6. Nav1.8-positive DRG neurons that did not express DREADD receptors had no change in action potential frequency after CNO application. (A-F)**


Representative traces from a Nav1.8-Cre;Ai9 primary cultured DRGs, which do not express DREADD receptors, from mice fed either RD (**A-C, blue**) or HFD (**D-F, red**). (**G**)

In both RD and HFD application of 2.5 $\mu$ M CNO did not change the action potential frequency (AP frequency) at either 1X or 2X rheobase current injection (RD n=4 for 1X and 2X; HFD n=4 for 1X and n=3 for 2X). Values are expressed as mean  $\pm$  S.E.M. p-values were calculated using Mann-Whitney test.

A





B





**Supplemental Figure 7. Injection of CNO decreases mechanical allodynia in inhibitory PDi DREADD expressing mice on HFD and had no effect on mice not expressing DREADD receptors.** (A) von Frey behavioral testing for Nav1.8-Cre:RC::PDi mice on either RD or HFD injected with a CNO (10 mg/kg) or saline intraperitoneally (i.p.). These mice expressed inhibitory DREADD receptors, PDi, in their Nav1.8-positive DRG neurons and fed a HFD showed an increase in pain withdrawal threshold one hour after CNO injection, this effect was absent four hours after injection (\*\*\*\*,  $p < 0.0001$ ) (n=16/group). (B) von Frey behavioral testing was also performed on Nav1.8-Cre;Ai9 mice that do not express inhibitory DREADD receptors. Mice were fed either RD or HFD and given an i.p. injection of either CNO (10 mg/kg) or saline. Mice on HFD had decreased withdrawal thresholds as expected and injection of CNO had no effect (\*\*\*\*,  $p < 0.0001$ ) (n=8/group). For both genotypes behavioral testing was done before the injection (time=0), one hour after the injection (time=1hr) and four hours after (time=4hr). Values are expressed as mean  $\pm$  S.E.M. p-values were calculated using a two-way ANOVA, Bonferroni multiple comparison test.

Na<sub>v</sub>1.8-Cre;RC::PDi mice  
(Inhibitory PDi)









Glucose Bolus at 120 mins

Na<sub>v</sub>1.8-Cre;Ai9 mice






Glucose Bolus at 120 mins

**Supplemental Figure 8. Expression of inhibitory DREADD receptors, PDi in Nav1.8-positive DRG neurons does not alter the metabolic profile in the HFD model.** (A) Weight of Nav1.8-Cre;RC::PDi mice in grams (gr) fed either RD or HFD for 10 weeks and injected with either CNO (10 mg/kg) or saline (\*\*\*\*,  $p < 0.0001$ ) (n=6/group). (B) Blood glucose levels of the same mice 120 minutes after injection of glucose (45% D-glucose solution (2 mg glucose/1 g animal body weight)) (\*\*\*\*,  $p < 0.0001$ ) (n=18/group). (C) Weight of Nav1.8-Cre;Ai9 mice fed either RD or HFD and injected with either CNO (10 mg/kg) or saline (\*\*\*,  $p < 0.001$ ) (n=6/group). (D) Blood glucose levels of the same mice 120 minutes after injection of glucose (\*,  $p < 0.05$ , \*\*,  $p < 0.01$ ) (n=18/group). Values are expressed as mean  $\pm$  S.E.M. p-values were calculated using one-way ANOVA, Bonferroni multiple comparison test.




**Supplemental Figure 9. Experimental plan, weights and blood glucose levels for prevention and reversal of PDN in mice that expressed inhibitory DREADD receptors, PDi.** (A) Experimental timeline for the prevention set of experiments where  $Na_v1.8-Cre;Ai9;RC::PDi$  mice were administered CNO (10 mg/kg/day) or saline through an osmotic mini-pump concurrently with mice being fed either RD or HFD. Each arrow represents a time point when weight and blood glucose levels were measured. (B) Weights of these mice in grams (gr) after 2 or 8 weeks on the diet (\*,  $p<0.05$ , \*\*,  $p<0.01$ , \*\*\*,  $p<0.001$ , \*\*\*\*,  $p<0.0001$ ) ( $n=6/group$ ). (C) Blood glucose levels of these mice at 2 and 8 weeks on diet 120 minutes after injection of glucose (45% D-glucose solution (2mg glucose/1g animal body weight)) (\*,  $p<0.05$ , \*\*,  $p<0.01$ ) ( $n=6/group$ ). (D) Experimental timeline for the reversal set of experiments where  $Na_v1.8-Cre;Ai9;RC::PDi$  mice were administered CNO (10 mg/kg/day) or saline through an osmotic mini-pump after being fed on diet. Each arrow represents a time point when weight and blood glucose levels were measured. (E) Weights of these mice in grams (gr) after 10 or 14 weeks on RD or HFD (\*,  $p<0.05$ , \*\*,  $p<0.01$ , \*\*\*,  $p<0.001$ , \*\*\*\*,  $p<0.0001$ ) ( $n=6/group$ ). (F) Blood glucose levels of these mice at 10 and 14 weeks on diet (\*,  $p<0.05$ , \*\*,  $p<0.01$ , \*\*\*,  $p<0.001$ , \*\*\*\*,  $p<0.0001$ ) ( $n=6/group$ ). Values are expressed as mean  $\pm$  S.E.M. p-values were calculated using two-way ANOVA, Bonferroni multiple comparison test.




**Supplemental Figure 10. Chemogenetic inhibition of Nav1.8-positive DRG neurons can prevent small-fiber degeneration visualized by either td-Tomato positive fibers or fibers stained with PGP 9.5.** (A) Experimental setup: osmotic mini-pumps infusing either CNO (10mg/kg/day) or saline were implanted i.p. in Nav1.8-Cre;Ai9;RC::PDi between 2 and 8 weeks of RD or HFD. (B) Confocal analysis of skin from these mice that express the inhibitory DREADD receptor, PDi, fed either RD or HFD showing td-Tomato (**red**) in Nav1.8-positive fibers, immunolabeling with antibody against PGP 9.5 (**green**), and merged images with the nuclear marker DAPI (**blue**). Mice on RD given either saline or CNO showed normal skin innervation. In diabetic mice given saline there was a reduction in skin innervation, but it was reversed for mice on HFD given CNO. CNO infusion prevented small-fiber degeneration of mice on HFD. Magnification 60x (scale bar=50µm). (C) This effect was quantified using intra-epidermal nerve density (IENF density) which is expressed as the number of nerves crossing the epidermal-dermal junction (outlined in white) as a function of epidermal-dermal junction length. IENF densities were calculated using both td-Tomato labeled fibers (shades of red) and PGP 9.5 labeled fibers (shades of green) (\*\*,  $p < 0.01$ , \*\*\*,  $p < 0.01$ ) (n=7 for all groups with 3 non-contiguous sections analyzed per sample). Values are expressed as mean  $\pm$  S.E.M. p-values were calculated using a two-way ANOVA with Dunnett Multiple comparison test.


A



B




C




**Supplemental Figure 11. Chemogenetic inhibition of Nav1.8-positive DRG neurons can reverse small-fiber degeneration visualized by either td-Tomato fibers or fibers stained with PGP 9.5.** (A) Experimental setup for the reversal set of experiments. Nav1.8-Cre;Ai9;RC::PDi were fitted with osmotic mini-pumps i.p. infusing either CNO (10mg/kg/day) or saline between 10-14 weeks of either RD or HFD. (B) Confocal analysis of skin from these mice that express the inhibitory DREADD receptor PDi fed either RD or HFD showing td-Tomato (**red**) in Nav1.8-positive fibers, immunolabeling with antibody against the protein gene product 9.5 (PGP 9.5) (**green**), and merged images with the nuclear marker DAPI (**blue**). Control mice on a RD with saline or CNO pumps showed normal skin innervation. Diabetic mice on HFD implanted with a saline pump showed reduced skin innervation. However, diabetic mice on a HFD fitted with CNO pumps showed a significant improvement in skin innervation. (C) This effect was quantified using intra-epidermal nerve density (IENF density) which is expressed as the number of nerves crossing the epidermal-dermal junction (outlined in white) as a function of epidermal-dermal junction length. IENF densities were calculated using both td-Tomato fibers (shades of red) and with PGP 9.5 fibers (shades of green) (n=6 from each group with 3 non-contiguous sections analyzed per sample). (\*, p<0.05, \*\*, p<0.01, \*\*\*, p<0.001). Values are expressed as mean  $\pm$  S.E.M. p-values were calculated using a two-way ANOVA with Dunnet Multiple comparison test.


A




B







C






D



**Supplemental Figure 12. Long-term treatment with CNO to prevent PDN onset has no effect on mice that do not express DREADD receptors.** (A) Experimental timeline for the prevention set of experiments where Nav1.8-Cre;Ai9 mice, that do not express DREADD receptors, are administered CNO (10 mg/kg/day) or saline through an osmotic mini-pump implanted i.p. concurrently with being fed either RD or HFD. Each arrow represents a time point where pain behavior is assessed. (B) von Frey behavioral testing was done at 2 and 8 weeks showing that HFD mice show a decreased withdrawal threshold only after being on the diet for 8 weeks. Treatment with CNO pump did not change the decreased withdrawal threshold observed in HFD mice and also had no effect on RD mice (\*\*,  $p < 0.01$ , \*\*\*,  $p < 0.001$ , \*\*\*\*,  $p < 0.0001$ ) ( $n = 6/\text{group}$ ). p-values were calculated using a two-way ANOVA with Bonferroni Multiple comparison test (C) Representative confocal micrographs taken from the skin of these animals showing the Nav1.8-positive fibers labeled with td-Tomato (**red**), immunolabeling for PGP 9.5 (**green**) and merged images with the nuclear marker DAPI (**blue**). Mice on HFD given CNO showed no change in skin innervation. Magnification 60x (scale bar=50 $\mu\text{m}$ ). (D) This effect was quantified using intra-epidermal nerve density (IENF density) which is expressed as the number of nerves crossing the epidermal-dermal junction (outlined in white) as a function of epidermal-dermal junction length. IENF densities were calculated using both td-Tomato fibers (shades of red) and with PGP 9.5 fibers (shades of green) (\*\*\*\*,  $p < 0.0001$ ) ( $n = 6/\text{group}$  with 3 non-contiguous sections analyzed per sample). Values are expressed as mean  $\pm$  S.E.M. p-values were calculated using a two-way ANOVA with Dunnet Multiple comparison test.



**Supplemental Figure 13. Long-term treatment to reverse PDN with CNO has no effect on mice that do not express DREADD receptors.** (A) Experimental timeline for the reversal set of experiments where Nav1.8-Cre;Ai9 mice are administered CNO (10 mg/kg/day) or saline through an osmotic mini-pump implanted i.p. following being fed either RD or HFD for 10 weeks. Each arrow represents a time point where pain behavior was assessed. (B) von Frey behavioral testing was done at 10 and 14 weeks showing that, as expected, mice on HFD given saline have a much lower withdrawal threshold compared to RD mice. When HFD mice were given CNO there is no change in the withdrawal threshold (\*\*,  $p < 0.01$ , \*\*\*,  $p < 0.001$ , \*\*\*\*,  $p < 0.0001$ ) ( $n = 6/\text{group}$ ). p-values were calculated using a two-way ANOVA, Bonferroni Multiple comparison test (C) Representative confocal micrographs taken from the skin of these animals showing the Nav1.8-positive fibers labeled with td-Tomato (**red**), immunolabeling for PGP 9.5 (**green**) and merged images with the nuclear marker DAPI (**blue**). Mice on HFD given CNO showed no improvement in skin innervation. Magnification 60x (scale bar=50 $\mu\text{m}$ ). (D) This effect was quantified using intra-epidermal nerve density (IENF density) which is expressed as the number of nerves crossing the epidermal-dermal junction (outlined in white) as a function of epidermal-dermal junction length. IENF densities were calculated using both td-Tomato fibers (shades of red) and with PGP 9.5 fibers (shades of green) (\*,  $p < 0.05$ , \*\*,  $p < 0.01$ , \*\*\*,  $p < 0.001$ ) ( $n = 6/\text{group}$  with 3 non-contiguous sections analyzed per sample). Values are expressed as mean  $\pm$  S.E.M. p-values were calculated using a two-way ANOVA with Dunnett Multiple comparison test.



**Supplemental Figure 14. Continuous CNO infusion did not alter the metabolic profile of mice expressing hM<sub>3</sub>Dq excitatory DREADD receptors.** (A) Experimental setup of osmotic mini-pump implantation in Na<sub>v</sub>1.8-Cre;RC::L-hM<sub>3</sub>Dq mice. Na<sub>v</sub>1.8-Cre;RC::L-hM<sub>3</sub>Dq mice that expressed excitatory hM<sub>3</sub>Dq DREADD receptors were fed either RD or HFD and had a osmotic mini-pump implanted intraperitoneally, which administered either saline or CNO (10mg/kg/day) for the period from 2 to 4 weeks following the commencement of HFD or RD. (B) Weights of these mice in grams (gr) after 2 or 4 weeks on the diet (\*, p<0.05, \*\*, <0.01) (n=6/group). (C) Blood glucose levels of these mice at two and four weeks on RD or HFD 120 minutes after injection of glucose (45% D-glucose solution (2mg glucose/1g animal body weight)) (n=6/group). Values are expressed as mean ± S.E.M. p-values were calculated using two-way ANOVA with Bonferroni Multiple comparison test.

**Supplemental Table 1: Electrophysiological parameters of neurons used for recordings of Figure 11.** Cells were recorded at culture days 2 – 4. For this dataset only a few medium and large neurons were included in the data. Values are expressed as mean  $\pm$  S.E.M.

Genotype (n)	Vm (mV)	capacitance (pF)	smallest (pF)	biggest (pF)	Rin (M $\Omega$ )	rheobase (pA)
Na <sub>v</sub> 1.8-Cre;Ai9 (16)	-61.3 $\pm$ 0.6	51.3 $\pm$ 11.7	20	196	501 $\pm$ 59	318.5 $\pm$ 108.25
Na <sub>v</sub> 1.8-Cre;RC::L-hM <sub>3</sub> Dq (28)	-62.8 $\pm$ 0.8	29.9 $\pm$ 1.7	19	53	641 $\pm$ 47	136 $\pm$ 22.7

**Supplemental Table 2:**  $[Ca^{2+}]_i$  responses of parvalbumin-Cre::GCaMP6 explants to CXCL12 or to different concentration of potassium buffer after 8 weeks on either diet (RD, n=88 neurons , 6 explants; HFD n=118, 9 explants). Values are expressed as mean  $\pm$  SEM. p-values were calculated using p- values were calculated using a Mann-Whitney test.

Parvalbumin-Cre::GCaMP6	CXCL12	HK10	HK25	HK50
R D	0	10.594 $\pm$ 3.4 1	22.818 $\pm$ 5.82	47.225 $\pm$ 2.3 4
HFD	3.33 $\pm$ 3.3 3	19.878 $\pm$ 9.2 3	37.288 $\pm$ 11.6 9	54.752 $\pm$ 9.5 7